Investing.com - Biomarin Pharma (NASDAQ:BMRN) reported on Tuesday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Biomarin Pharma announced earnings per share of $-0.16 on revenue of $429.5M. Analysts polled by Investing.com anticipated EPS of $-0.11 on revenue of $418.09M.
Biomarin Pharma shares are up 41.62% from the beginning of the year, still down 9.25% from its 52 week high of $131.95 set on July 21. They are outperforming the Nasdaq 100 which is up 27.06% from the start of the year.
Biomarin Pharma follows other major Healthcare sector earnings this month
Biomarin Pharma's report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Roche Holding ADR had beat expectations on July 23 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.43B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar